Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Cancer in inflammatory bowel disease

D R Bachwich¹, G R Lichtenstein, P G Traber

¹Department of Internal Medicine, University of Pennsylvania, Philadelphia.

The Medical Clinics of North America

|November 1, 1994

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology.

The American journal of gastroenterology·2020

Same author

Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.

Alimentary pharmacology & therapeutics·2016

Same author

Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.

Alimentary pharmacology & therapeutics·2014

Same author

Increased expression of interleukin-8 mRNA in ulcerative colitis and Crohn's disease mucosa and epithelial cells.

Inflammatory bowel diseases·2013

Same author

Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.

Alimentary pharmacology & therapeutics·2012

Same author

Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.

Alimentary pharmacology & therapeutics·2011

Patients with inflammatory bowel disease face higher risks of colorectal cancer. Options include surgery or surveillance, though surveillance effectiveness lacks data. Prophylactic colectomy is a viable option for select ulcerative colitis patients.

Area of Science:

Gastroenterology and Oncology
Inflammatory Bowel Disease Research

Background:

Patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease, have an elevated risk of gastrointestinal cancers, specifically colorectal adenocarcinoma.
Current strategies for mitigating this risk involve prophylactic colectomy, surveillance colonoscopy with colectomy for dysplasia, or no routine surveillance.

Purpose of the Study:

To review the current strategies for managing colorectal cancer risk in patients with inflammatory bowel disease.
To evaluate the role of surveillance colonoscopy and prophylactic colectomy in this patient population.

Main Methods:

Review of existing literature and clinical guidelines on colorectal cancer surveillance and management in IBD patients.
Analysis of the risks and benefits associated with different management approaches.

Related Experiment Videos

Main Results:

Surveillance colonoscopy is the current standard of care in the US, despite limited data supporting its effectiveness in reducing cancer risk.
Prophylactic colectomy, while less common, remains a significant option for select UC patients to reduce cancer risk.

Conclusions:

The optimal approach to managing colorectal cancer risk in IBD patients requires careful consideration of individual risk factors and available evidence.
Further research is needed to establish the definitive effectiveness of surveillance colonoscopy in IBD.
Prophylactic colectomy should be considered for appropriate UC patients.